MAPT and supranuclear palsy, progressive, 1: The main aim of this study was to optimize [18F]PI-2620 assessment as a 4R tau biomarker in PSP by addressing key limitations of the commonly used inferior cerebellar GM tau-PET reference [49], which is potentially confounded by adjacent cerebellar 4R tau accumulation [24, 33].